TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23785174

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT parameters
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Sum of SUV(max)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Maximum SUV(max)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Average SUV(max)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Sum of SUV(max) (quartile analysis)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Sum of SUV(max) (multivariable analysis)
Number of subjects: 87
Study: 23786166

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 5279

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 5279

Group type: COMPARATOR
Intervention: Cefuroxime and Metronidazole (combined)
Number of subjects: 5279

Group type: COMPARATOR
Intervention: Metronidazole alone
Number of subjects: 5279
Study: 23786513

Group type: EXPERIMENTAL
Intervention: Sexual risk-taking
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Sexual activity with multiple partners
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Biological testing for STI+
Number of subjects: 245
Study: 23786919

Group type: EXPERIMENTAL
Intervention: Clinical assessments including 6-minute walk test and 3-minute stair climb test
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Serum and urinary oligosaccharide levels analysis
Number of subjects: 43
Study: 23787231

Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR) in female patients (0.83 ± 0.09)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Reference vessel area in female patients (11.4 ± 3.3 mm²)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Vessel area in female patients (9.0 ± 3.3 mm²)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Plaque burden in female patients (69.8 ± 13.7%)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Positive predictive value of angiography in female patients (44%)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: IVUS-MLA concordance rate in female patients (64%)
Number of subjects: 700
Study: 23787357

Group type: EXPERIMENTAL
Intervention: MRI/US-fusion-guided biopsy
Number of subjects: 582

Group type: COMPARATOR
Intervention: 12-core biopsy
Number of subjects: 582
Study: 23787555

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (prednisone 1 mg/kg daily, max 60 mg/day) until complete remission, followed by gradual dosage reduction.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (prednisone)
Number of subjects: 27
Study: 23788609

Group type: EXPERIMENTAL
Intervention: Mechanical debridement and systemic antibiotics
Number of subjects: 59
Study: 23790554

Group type: EXPERIMENTAL
Intervention: Individual Burden of Illness index for Depression (IBI-D)
Number of subjects: 956
Study: 23790772

Group type: EXPERIMENTAL
Intervention: Neoadjuvant whole-pelvis radiation therapy (RT)
Number of subjects: 12
Study: 23790798

Group type: EXPERIMENTAL
Intervention: Decitabine treatment in RAEB-t group (n = 26)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Decitabine treatment in MDS group (n = 157)
Number of subjects: 183
Study: 23791392

Group type: EXPERIMENTAL
Intervention: EMD 525797 (250, 500, 1000, or 1500 mg every 2 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: EMD 525797 (500 mg cohort)
Number of subjects: 26
Study: 23791541

Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m² on day 1 and bortezomib 1.3 mg/m² on days 1, 4, 8, 11 every 3 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cisplatin and bortezomib
Number of subjects: 82
Study: 23792193

Group type: EXPERIMENTAL
Intervention: CTA/CTP
Number of subjects: 91

Group type: COMPARATOR
Intervention: CTA
Number of subjects: 91
Study: 23793683

Group type: EXPERIMENTAL
Intervention: Women's Health CoOp (WHC) intervention
Number of subjects: 720

Group type: COMPARATOR
Intervention: Nutrition intervention (control)
Number of subjects: 720

Group type: COMPARATOR
Intervention: HCT-only control
Number of subjects: 720
Study: 23793872

Group type: EXPERIMENTAL
Intervention: FLEX
Number of subjects: 35

Group type: COMPARATOR
Intervention: SMILE
Number of subjects: 35
Study: 23794578

Group type: EXPERIMENTAL
Intervention: Weekly WelTel SMS 'check-in'
Number of subjects: 686

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 686
Study: 23794582

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT-A)
Number of subjects: 456
Study: 23795577

Group type: EXPERIMENTAL
Intervention: LDMP 7.5 mg (single dose on day 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LDMP 7.5 mg (multiple doses, once daily for 14 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LDMP 7.5 mg
Number of subjects: 24
Study: 23795661

Group type: EXPERIMENTAL
Intervention: peg-IFNα-2a 180 μg per week and ribavirin 1000/1200 mg daily for 48 weeks (Group A)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: peg-IFNα-2a 180 μg per week and ribavirin 1000/1200 mg daily for 48 weeks (Group B)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: peg-IFNα-2a 180 μg per week and ribavirin 1000/1200 mg daily for 24 weeks (Group C)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: HCV RNA below 1000 IU/mL by day 6
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Detectable HCV RNA at week 12
Number of subjects: 71
Study: 23795975

Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator (glyburide, thiazolidinedione, or metformin)
Number of subjects: 0
Study: 23796131

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention promoting weight loss through decreased caloric intake and increased physical activity
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Diabetes support and education (control group)
Number of subjects: 5145
Study: 23796526

Group type: EXPERIMENTAL
Intervention: Behavioural modification and risk factor treatment
Number of subjects: 563
Study: 23796921

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 23799873

Group type: EXPERIMENTAL
Intervention: Temsirolimus added to standard therapy of Rituximab and DHAP
Number of subjects: 0
Study: 23799875

Group type: EXPERIMENTAL
Intervention: HAMD-BPRS11 rating scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAM-D6 rating scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 17-item Hamilton Depression Scale
Number of subjects: 0
Study: 23799932

Group type: EXPERIMENTAL
Intervention: Phaco-ELT (cataract surgery combined with excimer laser trabeculotomy)
Number of subjects: 64
Study: 23799943

Group type: EXPERIMENTAL
Intervention: MOHR assessment and subsequent counseling and support
Number of subjects: 9
Study: 23800144

Group type: EXPERIMENTAL
Intervention: Integrative medicine treatment approach for chronic pain
Number of subjects: 409
Study: 23800355

Group type: EXPERIMENTAL
Intervention: Implementation of one or more of 11 best practices for medication reconciliation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Baseline data collection on unintentional medication discrepancies
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Baseline data collection on history and reconciliation errors
Number of subjects: 6
Study: 23800418

Group type: EXPERIMENTAL
Intervention: Citalopram (STAR*D)
Number of subjects: 2093

Group type: EXPERIMENTAL
Intervention: Naturalistic setting (Italian sample)
Number of subjects: 2093
Study: 23800455

Group type: EXPERIMENTAL
Intervention: Fenestrated and branched endovascular aortic repair (FEVAR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 23800488

Group type: EXPERIMENTAL
Intervention: Higher discounting rates
Number of subjects: 30

Group type: COMPARATOR
Intervention: Executive attention control network
Number of subjects: 30
Study: 23800556

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 23801020

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with a defibrillator (CRT-D)
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator-only therapy
Number of subjects: 1197
Study: 23801633

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 60
Study: 23801798

Group type: EXPERIMENTAL
Intervention: Diabetes Assistant (DiAs) in closed-loop mode for 28 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diabetes Assistant (DiAs) in open-loop mode for 14 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diabetes Assistant (DiAs) overall system functionality
Number of subjects: 20
Study: 23803225

Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg every 2 weeks) and low-dose interferon-α2a (3 MIU thrice weekly)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Bevacizumab plus interferon-α2a (9 MIU) from AVOREN study
Number of subjects: 146
Study: 23803880

Group type: EXPERIMENTAL
Intervention: 5 servings of fruit and vegetables per day
Number of subjects: 71706

Group type: EXPERIMENTAL
Intervention: 1 fruit per day
Number of subjects: 71706

Group type: EXPERIMENTAL
Intervention: 3 vegetables per day
Number of subjects: 71706
Study: 23804252

Group type: EXPERIMENTAL
Intervention: Inducible ischemia added to multivariable clinical risk model
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Inducible ischemia
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Inducible ischemia in patients with previous coronary artery disease
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Categorical net reclassification index
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Continuous net reclassification improvement
Number of subjects: 815
Study: 23805209

Group type: EXPERIMENTAL
Intervention: HSV-2 infection
Number of subjects: 13735

Group type: EXPERIMENTAL
Intervention: Lifetime sexual partners
Number of subjects: 13735

Group type: EXPERIMENTAL
Intervention: ≥2 partners in the past year
Number of subjects: 13735

Group type: EXPERIMENTAL
Intervention: ≥2 new partners in the past year
Number of subjects: 13735

Group type: EXPERIMENTAL
Intervention: Concurrent partners in the past year
Number of subjects: 13735
Study: 23805387

Group type: EXPERIMENTAL
Intervention: 0.008% indigocarmine added to the water method
Number of subjects: 168

Group type: COMPARATOR
Intervention: Water method (control)
Number of subjects: 168
Study: 23805395

Group type: EXPERIMENTAL
Intervention: Warm water infusion colonoscopy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Conventional air insufflation colonoscopy
Number of subjects: 3
Study: 23806958

Group type: EXPERIMENTAL
Intervention: Titanium-coated polypropylene mesh
Number of subjects: 207
Study: 23808960

Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg/day)
Number of subjects: 528
Study: 23809138

Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy with atorvastatin 40 mg and ezetimibe 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23809203

Group type: EXPERIMENTAL
Intervention: Positive family history (FH) of aortic aneurysms
Number of subjects: 426
Study: 23809536

Group type: EXPERIMENTAL
Intervention: 25(OH)D
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: DBP
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: 25(OH)D and DBP
Number of subjects: 498
Study: 23809766

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily in cycles of 3 weeks on/1 week off treatment until disease progression, unacceptable toxicity, death or patient/physician decision to discontinue.
Number of subjects: 36
Study: 23810300

Group type: EXPERIMENTAL
Intervention: Operator
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Anesthesia
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Scrub Nurse
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Radiologic Technologist (RT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Field Size Decrease
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lateral Angulation of C-arm
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Digital Subtraction Acquisitions
Number of subjects: 39
Study: 23810467

Group type: EXPERIMENTAL
Intervention: Cediranib 30 mg daily and olaparib 200 mg BID
Number of subjects: 28
Study: 23810788

Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Niraparib 30 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Niraparib 60 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Niraparib 400 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Niraparib (various doses)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Niraparib (doses >80 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Niraparib (doses >60 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Niraparib in BRCA1 or BRCA2 mutation carriers with ovarian cancer
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Niraparib in BRCA1 or BRCA2 mutation carriers with breast cancer
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Niraparib in sporadic high-grade serous ovarian cancer, non-small-cell lung cancer, and prostate cancer
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 100
Study: 23810884

Group type: EXPERIMENTAL
Intervention: OCT-erosion
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: OCT-CN
Number of subjects: 126
Study: 23812930

Group type: EXPERIMENTAL
Intervention: Lenalidomide (15 mg/day on days 1-14) in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lenalidomide (15 mg/day)
Number of subjects: 21
Study: 23812932

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg intravenous every 21 days)
Number of subjects: 11
Study: 23813557

Group type: EXPERIMENTAL
Intervention: Indoxyl sulfate
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: p-Cresyl sulfate
Number of subjects: 203
Study: 23813757

Group type: EXPERIMENTAL
Intervention: Skin intrinsic fluorescence (SIF)
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Skin intrinsic fluorescence (SIF) in the intensive treatment group
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Skin intrinsic fluorescence (SIF) in the conventional treatment group
Number of subjects: 1185
Study: 23813900

Group type: EXPERIMENTAL
Intervention: Fludarabine-based PBPC transplantation
Number of subjects: 56
Study: 23815472

Group type: EXPERIMENTAL
Intervention: TDF+PI/r
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 23815563

Group type: EXPERIMENTAL
Intervention: TBI Common Data Elements (TBI-CDEs)
Number of subjects: 650
Study: 23815876

Group type: EXPERIMENTAL
Intervention: FOXP1 gene transcript in lymphoblastoid cell lines (LCL)
Number of subjects: 16
Study: 23815981

Group type: EXPERIMENTAL
Intervention: FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody in combination with donor lymphocyte infusion (DLI)
Number of subjects: 24
Study: 23816016

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice a day for 1 month for patients ≥70 kg; 0.5 mg once for patients <70 kg or intolerant)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 360
Study: 23816032

Group type: COMPARATOR
Intervention: No CAD
Number of subjects: 917

Group type: COMPARATOR
Intervention: Nonobstructive CAD
Number of subjects: 917

Group type: COMPARATOR
Intervention: Obstructive CAD
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: WISE CAD severity score >10
Number of subjects: 917
Study: 23816330

Group type: EXPERIMENTAL
Intervention: Extended criteria organs (BMI 30-34 or donor age 50-60)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard criteria organs (BMI <30 and donor age <50)
Number of subjects: 0
Study: 23816920

Group type: EXPERIMENTAL
Intervention: Omalizumab (n = 4), administered every 2-4 weeks over 24 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (n = 4), administered every 2-4 weeks over 24 weeks
Number of subjects: 8
Study: 23816963

Group type: EXPERIMENTAL
Intervention: Afatinib 50 mg per day
Number of subjects: 62
Study: 23817375

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) at 50 mg daily for 5 days followed by DTG with prednisone at 60 mg daily for 10 days (5 days high-dose followed by 5-day taper)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) at 50 mg daily for 5 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dolutegravir and prednisone coadministration
Number of subjects: 12
Study: 23817567

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 0
Study: 23817577

Group type: EXPERIMENTAL
Intervention: Pressure-derived collateral flow index (CFIp) during resting conditions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Toe oxygen saturation (Sao2) during resting conditions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CFIp during exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sao2 during exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pain or cramps/tired muscles during exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Relationship between CFIp and pain-free time span
Number of subjects: 30
Study: 23817721

Group type: EXPERIMENTAL
Intervention: Dendritic cell-based vaccine targeting CSCs
Number of subjects: 7

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 7
Study: 23817974

Group type: EXPERIMENTAL
Intervention: TAK-285 (400 mg twice daily)
Number of subjects: 54
Study: 23818263

Group type: EXPERIMENTAL
Intervention: Nonadjuvant influenza A H1N1 vaccine in juvenile SLE patients
Number of subjects: 118

Group type: COMPARATOR
Intervention: Healthy controls vaccinated with nonadjuvant influenza A H1N1 vaccine
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Juvenile SLE patients with SLEDAI-2K score ≥8
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: SLEDAI-2K score ≥8 as a factor for nonseroconversion
Number of subjects: 118
Study: 23818490

Group type: EXPERIMENTAL
Intervention: Obese African-American girls
Number of subjects: 76

Group type: COMPARATOR
Intervention: Latina girls
Number of subjects: 76
Study: 23819100

Group type: EXPERIMENTAL
Intervention: Drainage (group 2)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Nondrainage (group 1)
Number of subjects: 400
Study: 23819769

Group type: EXPERIMENTAL
Intervention: Two-thumb encircling hands technique
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Two-thumbs direct compression technique
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Classic one-hand technique with sternal accelerometer
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Restoration of spontaneous circulation (ROSC)
Number of subjects: 1
Study: 23820296

Group type: EXPERIMENTAL
Intervention: Lumbar Fusion (LF)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Conservative Treatment (Control)
Number of subjects: 666
Study: 23820600

Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 33
Study: 23821658

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: -1
Study: 23822525

Group type: EXPERIMENTAL
Intervention: Initial triage priority (high vs. low priority) adjudicated by the attending ED physician at ED discharge
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Adverse 30 day outcome (death or intensive care unit admission)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Post-acute care needs after hospital discharge (transfer to a post-acute care institution)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Time to first physician contact
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Time to initiation of adequate medical therapy
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Time to social worker involvement
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Reasons for discharge delays
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Patient's satisfaction with care
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Overall hospital costs
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Patient's care needs after returning home
Number of subjects: 6000
Study: 23822537

Group type: EXPERIMENTAL
Intervention: Panobinostat treatment
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: TARC reductions > median at C1D15
Number of subjects: 129
Study: 23823198

Group type: EXPERIMENTAL
Intervention: Interleukin-16
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Interleukin-6
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Combination of interleukin-16 and 10-minute Apgar score
Number of subjects: 130
Study: 23823332

Group type: EXPERIMENTAL
Intervention: 2,500 sporozoites intradermally (ID)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2,500 sporozoites intramuscularly (IM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 25,000 sporozoites intramuscularly (IM)
Number of subjects: 18
Study: 23823978

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 402
Study: 23824037

Group type: EXPERIMENTAL
Intervention: Citrate infusion in critically ill patients with AKI
Number of subjects: 12

Group type: COMPARATOR
Intervention: Citrate infusion in healthy volunteers
Number of subjects: 12
Study: 23824312

Group type: EXPERIMENTAL
Intervention: Complex intervention facilitating early cancer rehabilitation by involvement of the general practitioner (GP) soon after diagnosis.
Number of subjects: 955

Group type: COMPARATOR
Intervention: Control group (standard care without the intervention).
Number of subjects: 955
Study: 23824363

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT) delivering accelerated partial breast irradiation (APBI) at a dose of 38.5 Gy in 10 equal fractions delivered twice daily.
Number of subjects: 136
Study: 23824723

Group type: EXPERIMENTAL
Intervention: Lower ratio of n-6 to n-3 fatty acids
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Higher intake of n-3 fatty acids with high n-6 to n-3 ratio
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lower intake of n-3 and lower intake of n-6 with low n-6 to n-3 ratio
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mean n-3 and mean n-6 intakes
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ratio of n-6 to n-3
Number of subjects: 70